Both Bernie Sanders and Hillary Clinton have made healthcare a central part of their campaigns, and while Sanders looks to revolutionize the country’s entire healthcare system, Clinton is focusing her sights squarely on Big Pharma.
“At that time it cost approximately $180 for 10 shots,” Clinton tells the crowd. “The latest refill was $14,700 for the same 10 vials. And the company, is called Valeant Pharmaceuticals… I’m going after them.”
That made Shkreli the face of the evil pharmaceutical industry and an easy target for politicians like Hillary Clinton to attack on the campaign trail. But as soon as she did, the media quickly pointed out how much money the Clinton campaign has received from the Pharmaceutical industry (hint: it’s a lot).
But Clinton is adamant that the money she has gotten from Wall Street won’t stop her from being tough on financial institutions, so maybe the same goes for Big Pharma too.
Take On the Drug Companies… But Not Obamacare
“Predatory” features Clinton reading a voter’s letter at an early campaign rally in Iowa. Clinton explains that this person had been taking a brand name drug since the early 1980s.“At that time it cost approximately $180 for 10 shots,” Clinton tells the crowd. “The latest refill was $14,700 for the same 10 vials. And the company, is called Valeant Pharmaceuticals… I’m going after them.”
Will Clinton Use Her Donations from Big Pharma to ‘Go After’ Big Pharma?
Earlier in the campaign cycle, Turing Pharmaceutical CEO Martin Shkreli became one of the most hated men in America, when his company bought the rights to the lifesaving HIV drug, Daraprim, and jacked the price up nearly 5,000%.That made Shkreli the face of the evil pharmaceutical industry and an easy target for politicians like Hillary Clinton to attack on the campaign trail. But as soon as she did, the media quickly pointed out how much money the Clinton campaign has received from the Pharmaceutical industry (hint: it’s a lot).
But Clinton is adamant that the money she has gotten from Wall Street won’t stop her from being tough on financial institutions, so maybe the same goes for Big Pharma too.